Telomerase Inhibitors as Anticancer Therapy

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Telomerase Inhibitors as Anticancer Therapy

Anti-Cancer Agents in Medicinal Chemistry, 2(5): 567-575.

Author(s): Masaharu Akiyama, Teru Hideshima, Nikhil C. Munshi and Kenneth C Anderson.

Affiliation: Dana-Farber Cancer Institute,44 Binney Street, Boston, MA 02115, USA


Telomerase inhibitors have been touted as a novel cancer specific therapy, as most tumor cells have high expression of telomerase, whereas most normal somatic cells express low or undetectable levels of telomerase. Continued proliferation of tumor cells requires activation of telomerase to maintain chromosomal stability and extend life span, because telomerase elongates telomere length and rewinds the cellular mitotic clock. Conversely, shortening of telomeres by inhibition of telomerase activity induces growth arrest (senescence) and apoptosis in tumor cells. Moreover, it has been reported that inhibition of telomerase increases the susceptibility of tumor cells to apoptosis induced by anticancer agents. Thus, telomerase inhibitors could be used as an adjuvant with conventional therapy. However, there are also several potential limitations of telomerase inhibition as a therapeutic strategy. For example, there is a lag phase between telomerase inhibition and telomere shortening, with growth arrest and cell death. In this review, we will discuss the basic biology of telomeres and telomerase as a platform for the development of treatments based upon inhibition of telomerase activity.


Telomerase Inhibitors, Anticancer Therapy, Immunotherapy, Catalytic Inhibitors, G-quadruplex Interactive Agents, hTERT Constructs, Hammerhead Ribozymes, Antisense Oligonucleotides.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 2
Issue Number: 5
First Page: 567
Last Page: 575
Page Count: 9
DOI: 10.2174/1568011023353778
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science